An emerging biotech company clearly relies on its scientific prowess to develop an asset that can be efficacious. Throughout development, this scientific “weight” is valuable but too often, promising science is unable to overcome underfunded and under-planned commercial strategy. As emerging biotech companies find the right path to commercialization for their organization, there are key questions to consider when determining if your organization is aligned for commercial success.
Applying a commercial lens from the outset can help companies stay on course and enhance commercial viability.
Watch this webinar to learn more about preparing and aligning your company for commercial success, featuring Lee Taurman, Executive Vice President of Full-Service Commercial at Syneos Health and executives from Novan and VBI Vaccines.
